NIRV — Nirvana Life Sciences Share Price
Last trade - 00:00- CA$0.48m
- CA$0.50m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Apr | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nirvana Life Sciences Inc. is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The Company has selected two products for its first phase of development: a one-per-day slow release gel cap that assists transition from opioids to non-addictive pain relief therapies, and a one-per-day slow release gel cap that delivers non-addictive pain relief. Any number of therapeutic medicines and products are created from its formulations. The Company is also engaged in growing several genera and species of fungi (including rare and hybrid varieties) with a batch consistency.
Directors
- Last Annual
- April 30th, 2023
- Last Interim
- January 31st, 2024
- Incorporated
- November 1st, 2020
- Public Since
- March 17th, 2022
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 48,233,010
- Address
- 2100, 650 West Georgia Street, VANCOUVER, V6B 4N8
- Web
- https://nirvanalifescience.com/
- Phone
- +1 6046891280
- Auditors
- DALE MATHESON CARR-HILTON LABONTE LLP
Similar to NIRV
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
FAQ
As of Today at 22:21 UTC, shares in Nirvana Life Sciences are trading at CA$0.01. This share price information is delayed by 15 minutes.
Shares in Nirvana Life Sciences last closed at CA$0.01 and the price had moved by -75% over the past 365 days. In terms of relative price strength the Nirvana Life Sciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -77.48% over the past year.
There is no consensus recommendation for this security.
Nirvana Life Sciences does not currently pay a dividend.
Nirvana Life Sciences does not currently pay a dividend.
Nirvana Life Sciences does not currently pay a dividend.
To buy shares in Nirvana Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.01, shares in Nirvana Life Sciences had a market capitalisation of CA$0.48m.
Here are the trading details for Nirvana Life Sciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: NIRV
Based on an overall assessment of its quality, value and momentum Nirvana Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nirvana Life Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -51.25%.
As of the last closing price of CA$0.01, shares in Nirvana Life Sciences were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nirvana Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Nirvana Life Sciences' directors